IHMA

In case you missed it – see IHMA’s co-authored posters presented at #ESCMIDGlobal2025 on the IHMA Publications page, linked here: https://lnkd.in/gA7AKh7 Thank you to all that stopped by – see you next year in Munich, Germany! #ESCMIDGlobal Pictured presenters: Mark Estabrook, Dana Dressel, Christina Streit, Henry Li, Darcie Carpenter

#ESCMIDGlobal2025 Final Day: Stop by IHMA’s exhibitor’s booth E-87 and the final co-authored #poster presentation!

As #ESCMIDGlobal2025 has kicked off – make sure to stop by IHMA’s 30 co-authored posters: • 4 posters presented TODAY, Sunday April 13th, • 25 posters presented TOMORROW, Monday April 14th • 1 poster presented TUESDAY, April 15th See you there!

The #ESCMID Global Congress has begun in Vienna, Austria! Meet the IHMA Team TODAY in the main exhibitor’s hall at Booth E-87. #ESCMIDGlobal2025 Link: https://lnkd.in/gcACZQ-4

📢 Meet our PACE Delivery Partners! Innovators require support to accelerate the progress of their antimicrobial and diagnostic discovery projects. To address this, we’ve convened a Delivery Partner Network (DPN), bringing together providers to enable all aspects of outsourced project work. Members of the DPN are organisations that can help with delivery, advice and support for PACE-funded projects. Our aim is to connect the projects in our portfolio to the DPN, looking for ways in which our Partners can enable outsourced lab work, as well as provide expert consultancy in key areas. The services offered by the DPN are also useful to innovators in the wider AMR R&D community. We have partnered with these organisations because they provide a breadth and depth of expertise that are critical to support early antimicrobial drug and diagnostic discovery. If you’re an innovator working in this space and you are looking to do some outsourced work, you can Contact Us (see link in comments) and we can facilitate introductions to DPN members of your choice. 🔗 You can find more details of our Delivery Partners here: https://lnkd.in/eURbBqd9 ApconiX BioAscent Domainex Absolute Antibody Pharmidex IHMA Abingdon Health plc Evotec CPI Boyds TTP plc Charles River Laboratories Concept Life Sciences Fios Genomics APIS Assay Technologies Ltd. Biofortuna BBI Solutions #PACE #DeliveryPartnerNetwork #AMR

Join ANTABIO at #ESCMIDGlobal2025 in Vienna, Austria, from April 11-15, 2025! Discover our latest data and the exciting advancements we're making with our clinical program, #MEM_ANT3310. #MEM_ANT3310 is being developed for the treatment of serious infections such as hospital-acquired bacterial pneumonia (#HABP) and ventilator-associated bacterial pneumonia (#VABP), which can be caused by multidrug-resistant pathogens, including Carbapenem-Resistant Enterobacterales (#CRE) and Carbapenem-Resistant Acinetobacter baumannii (#CRAB). Check out the posters and presentations below, and don't hesitate to reach out to us and to our fantastic collaborators to learn more! **************************************************** #Oral_Presentation_E0475 (#TopRatedAbstract). Broad spectrum coverage of serine β-lactamase and high in vitro potency against KPC and OXA-48-like-producing Enterobacterales of meropenem in combination with the novel diazabicyclooctane β-lactamase inhibitor #ANT3310. A work conducted and presented by the University Hospital A Coruña (#CHUAC). Arena 4. Sunday 13th April, 4:15pm. #Poster_P2356. Disarming carbapenemase-producing Acinetobacter baumannii: high potency of the novel therapeutic combination of meropenem with the diazabyciclooctane β-lactamase inhibitor #ANT3310. A work conducted and presented by the University Hospital A Coruña (#CHUAC) #Poster_P2447. Pharmacokinetics-Pharmacodynamics of #ANT3310, in Combination with Meropenem, Against Carbapenem-Resistant Enterobacterales Using a Neutropenic Murine Acute Pyelonephritis Model. Presented by #ICPD #Poster_P5021. Evaluation of the Activity of the Novel Antibiotic Combination #Meropenem_ANT3310 against Recent Multidrug-resistant Enterobacterales and Acinetobacter baumannii Clinical Isolates. Presented by IHMA *******************************************************************

The IHMA team forward to this new conference about AMR.

New news: The FDA LDT Final Rule scheduled to go into effect on May 6th has been set aside by the courts. Find the full text here (Memorandum & Opinion AND Order): https://hubs.la/Q03fd5Zj0 and here (Judgment): https://hubs.la/Q03fdnpp0. What does that mean for LDTs? For now, it is status quo. The CLIA program retains regulation of laboratories that develop LDTs. What you should know? Quality testing is important and legislation and regulatory ambiguity is a persistent challenge. We're here to support laboratories and manufacturers with the guidance, tools, and resources needed to ensure they are equipped for any outcome. #LDT #FDA FDA

The World Health Organization released its first analysis of the clinical and pre-clinical antifungal pipeline, and the findings are cause for concern. They include: -Globally, only 4 new antifungals were approved during the last 10 years -Only 9 agents are currently in clinical development against priority fungal pathogens - Antifungals with child-friendly formulations for pediatric use are lacking - Fungal infections contribute to 3.8 million deaths globally each year As our CEO Henry Skinner warned two years ago in STAT, investment in this area is sorely lacking with some estimates indicating that fungal infections receive less than 1.5% of all infectious disease research funding. In the absence of policy interventions, investment into this critical area of medicine will remain insufficient and patients will continue to suffer. Read WHO’s full report: https://lnkd.in/eDQsx36x Read the Stat op-ed: https://lnkd.in/dUKKrMGU

Join IHMA 11-15 April at #ESCMID Global in Vienna, Austria!  Stop by Booth E87 or any of our 30 co-authored posters. #ESCMIDGlobal2025 Congress Website: https://lnkd.in/gFXwRhKp